Published ahead of print on June 19, 2003, doi:10.1164/rccm.200209-982OC
American Journal of Respiratory and Critical Care Medicine Vol 168. pp. 1075-1083, (2003)
© 2003 American Thoracic Society
Redox-active Protein Thioredoxin Prevents Proinflammatory Cytokine- or Bleomycin-induced Lung Injury
Tomoaki Hoshino,
Hajime Nakamura,
Masaki Okamoto,
Seiya Kato,
Shinichi Araya,
Keiko Nomiyama,
Kotaro Oizumi,
Howard A. Young,
Hisamichi Aizawa and
Junji Yodoi
Departments of Internal Medicine 1 and Pathology, Kurume University, Kurume, Fukuoka; Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto, Japan; and Laboratory of Experimental Immunology, DBS, NCI-Frederick, Frederick, Maryland
Correspondence and requests for reprints should be addressed to Tomoaki Hoshino, Department of Internal Medicine 1, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. E-mail: hoshino{at}med.kurume-u.ac.jp
Thioredoxin (TRX) is a multifunctional redox (reduction/oxidation)-active protein that scavenges reactive oxygen species by itself or together with TRX-dependent peroxiredoxin. TRX also has chemotaxis-modulating functions and suppresses leukocyte infiltration into sites of inflammation. Leukocyte infiltration and oxidative stress may be involved in the pathogenesis of several diseases, including interstitial lung diseases (ILD). We examined the effects of TRX in two mouse models of human ILD. Recently, we established a new mouse model for human ILD in which daily administration of proinflammatory cytokine interleukin (IL)-18 with IL-2 induces lethal lung injury accompanied by acute interstitial inflammatory responses. Administration of recombinant TRX suppressed IL-18/IL-2induced interstitial infiltration of cells and prevented death and lung tissue damage. TRX-transgenic mice also showed resistance to lethal lung injury caused by IL-18/IL-2. Administration of bleomycin induces the infiltration of polymorphonuclear and mononuclear leukocytes in the pulmonary interstitium, followed by progressive fibrosis. Wild-type mice given recombinant TRX treatment and TRX-transgenic mice demonstrated a decrease in bleomycin-induced cellular infiltrates and fibrotic changes in the lung tissue. These results suggest that TRX modulates pulmonary inflammatory responses and acts to prevent lung injury. TRX may have clinical benefits in human ILD, including lung fibrosis, for which no effective therapeutic strategy currently exists.
Key Words: thioredoxin redox interstitial lung diseases cytokine bleomycin
This article has been cited by other articles:

|
 |

|
 |
 
A. R. Hemnes, A. Zaiman, and H. C. Champion
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation
Am J Physiol Lung Cell Mol Physiol,
January 1, 2008;
294(1):
L24 - L33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Tipple, S. E. Welty, L. K. Rogers, T. N. Hansen, Y.-E. Choi, J. P. Kehrer, and C. V. Smith
Thioredoxin-Related Mechanisms in Hyperoxic Lung Injury in Mice
Am. J. Respir. Cell Mol. Biol.,
October 1, 2007;
37(4):
405 - 413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hoshino, S. Kato, N. Oka, H. Imaoka, T. Kinoshita, S. Takei, Y. Kitasato, T. Kawayama, T. Imaizumi, K. Yamada, et al.
Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13
Am. J. Respir. Crit. Care Med.,
July 1, 2007;
176(1):
49 - 62.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ohashi, A. Nishio, H. Nakamura, M. Kido, S. Ueno, N. Uza, S. Inoue, H. Kitamura, K. Kiriya, M. Asada, et al.
Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis
Am J Physiol Gastrointest Liver Physiol,
April 1, 2006;
290(4):
G772 - G781.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. YOSHIDA, H. NAKAMURA, H. MASUTANI, and J. YODOI
The Involvement of Thioredoxin and Thioredoxin Binding Protein-2 on Cellular Proliferation and Aging Process
Ann. N.Y. Acad. Sci.,
December 1, 2005;
1055(1):
1 - 12.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zieker, E. Fehrenbach, J. Dietzsch, J. Fliegner, M. Waidmann, K. Nieselt, P. Gebicke-Haerter, R. Spanagel, P. Simon, A. M. Niess, et al.
cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise
Physiol Genomics,
November 17, 2005;
23(3):
287 - 294.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. E. Lawson, V. V. Polosukhin, O. Zoia, G. T. Stathopoulos, W. Han, D. Plieth, J. E. Loyd, E. G. Neilson, and T. S. Blackwell
Characterization of Fibroblast-specific Protein 1 in Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med.,
April 15, 2005;
171(8):
899 - 907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
288 - 300.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Crapo
Redox Active Agents in Inflammatory Lung Injury
Am. J. Respir. Crit. Care Med.,
November 1, 2003;
168(9):
1027 - 1028.
[Full Text]
|
 |
|
Copyright © 2003 American Thoracic Society
|
|
|